Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Surprising discovery provides insights into aggressive endometrial cancers

New research from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) indicates steroid and hormone receptors are simultaneously active in many endometrial cancer tissues.

The findings, published today in the journal Cell Reports, yield insights about factors that contribute to more aggressive endometrial tumours.

The study was led by Jay Gertz, PhD, a cancer researcher at HCI and an assistant professor of Oncological Sciences at the U of U. Gertz and his colleagues focused on the endometrium, the interior lining of the uterus.

The researchers were surprised to discover that two receptors - oestrogen and glucocorticoid - which have opposing effects on normal growth of the uterine lining, work together to promote more aggressive endometrial cancers.

They found that endometrial tumours with high oestrogen receptor expression have a poor prognosis if they also have high amounts of glucocorticoid receptor - a stress hormone receptor.

Gertz and his colleagues, including Maggie Janat-Amsbury, MD, PhD and other members of HCI's Women's Cancer Disease-Oriented Research Team, used publicly available databases, mouse models, 3-D cultures, and genomic analyses to get a picture of how the two different receptors work together.

Using the National Institutes of Health Cancer Genome Atlas Project, researchers were able to find the connection between oestrogen receptor and a gene they didn't know was related in endometrial cancer - the glucocorticoid receptor.

"We know about oestrogen's role in the disease but what's interesting is we have a stress signal coming in and affecting the tumour's biology," said Gertz.

During the two-year-long project, researchers studied the effects of oestrogen and corticosteroids on the endometrium in mice using a cancer precursor model developed by the Janát-Amsbury lab.

They discovered corticosteroids made the lining of the uterus stop growing, but once the mice were given high doses of oestrogen the growth suppression was lost.

"Going into the study we would have thought that cortisol and corticosteroids would inhibit the formation of tumours and lead to less aggressive tumours, so our results were very surprising," according to Gertz.

The study encourages further evaluation of dexamethasone, a drug commonly prescribed to treat side effects from surgery and chemotherapy in cancer patients.

Gertz cautions more research needs to be done, including human clinical trials, before making any conclusions related to this drug.

Approximately 60,000 women in the United States are diagnosed with endometrial cancer every year.

It's considered the most common gynaecological cancer and is one of the only cancers increasing in both diagnoses and deaths.

Endometrial cancer predominantly affects women over 60, but Janát-Amsbury says that's changing, "There's not a simple answer as to why younger women are being diagnosed with endometrial cancer, but obesity is a component." Janát-Amsbury notes a recent HCI study showing a link between adipose (fat) tissue and endometrial cancer.

Overweight or obese women with adipose tissue produce more oestrogen.

"The adipose tissue works a little bit like an oestrogen factory," she said.

The next step is a better understanding of the mechanisms connecting oestrogen and glucocorticoid pathways, how they are triggered, and how these findings translate to patients through clinical trials.

"I think the key thing to take from this is we have to retrain ourselves in how we treat and evaluate these cancers as we learn these molecular nuances," said Janát-Amsbury.

Source: Huntsman Cancer Institute

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence